Linked Life Data

18443257

Source:http://linkedlifedata.com/resource/pubmed/id/18443257

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2008-4-29
pubmed:abstractText
A recent publication from the HORIZON (Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly) trial in women with postmenopausal osteoporosis reported a higher risk of serious atrial fibrillation (AF) in zoledronic acid recipients than in placebo recipients. This adverse effect was unexpected and had not been recognized previously.
pubmed:grant
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1538-3679
pubmed:author
pubmed:issnType
Electronic
pubmed:day
28
pubmed:volume
168
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
826-31
pubmed:dateRevised
2008-12-18
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Use of alendronate and risk of incident atrial fibrillation in women.
pubmed:affiliation
Cardiovascular Health Research Unit, University of Washington, 1730 Minor Ave, Ste 1360, Seattle, WA 98101-1448, USA. heckbert@u.washington.edu
pubmed:publicationType
Journal Article, Research Support, N.I.H., Extramural